IQVIA

Commercial

Caroline O'Leary - Chief Investigator - IQVIAMinouk Schoemaker - Corresponding Applicant - IQVIAClare Flach - Collaborator - IQVIAHeloísa Galante - Collaborator - IQVIAJoshua Warden - Collaborator - IQVIAMar Pujades Rodriguez - Collaborator - IQVIANelly Ly - Collaborator - IQVIASander Van Olst - Collaborator - IQVIAStephanie Castello - Collaborator - IQVIA

CPRD10

Chronic obstructive pulmonary disease (COPD) is a common lung condition that causes breathing difficulties such as breathlessness, coughing and wheezing. As these symptoms get worse, it can lead to the patient needing to be treated in hospital and may lead to death. The severity of the disease is measured on a scale ranging from mild, moderate, severe to very severe. This study focuses on those with moderate-to-very-severe COPD. The study aims to investigate risk of death from all causes, understand which factors influence the risk of death, and describe medication used in patients diagnosed with moderate-to-very-severe COPD in England.

This is an observational retrospective cohort study using CPRD-HES-ONS linked data aiming to describe treatment patterns and mortality among moderate-to-very-severe COPD patients in England, and to investigate risk factors for receiving particular treatments, death and other COPD-related outcomes. The study will include COPD patients who are eligible for linkage to HES and ONS. HES data will be used to determine COPD exacerbations, while ONS data will be used to obtain details on deaths.

15/06/2021

Release